Last reviewed · How we verify

NCT04074785: SCCC-06319

Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6

Terminated EARLY_PHASE1 Last updated 17 August 2025
What this trial tests

EARLY_PHASE1 trial testing Abemaciclib in GBM in 10 participants. Terminated before completion.

Timeline
13 December 2019
Primary endpoint
16 October 2023
16 October 2023

Quick facts

Lead sponsorUniversity of Texas Southwestern Medical Center
PhaseEARLY_PHASE1
StatusTerminated
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment10
Start date13 December 2019
Primary completion16 October 2023
Estimated completion16 October 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Texas Southwestern Medical Center

Who can join

Adults 18 to 99, any sex, with GBM or Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Describe the safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. CDK4 and CDK6 kinases: From basic science to cancer therapy.
    Fassl A, Geng Y, Sicinski P. · · 2022 · cited 351× · PMID 35025636 · DOI 10.1126/science.abc1495
  2. Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs.
    Yuan K, Wang X, Dong H, Min W, et al · · 2021 · cited 103× · PMID 33532179 · DOI 10.1016/j.apsb.2020.05.001
  3. Glioblastoma at the crossroads: current understanding and future therapeutic horizons.
    Singh S, Dey D, Barik D, Mohapatra I, et al · · 2025 · cited 91× · PMID 40628732 · DOI 10.1038/s41392-025-02299-4
  4. Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds.
    Liu H, Qiu W, Sun T, Wang L, et al · · 2022 · cited 58× · PMID 35847506 · DOI 10.1016/j.apsb.2021.12.019
  5. Pathogenetic Features and Current Management of Glioblastoma.
    Nguyen HM, Guz-Montgomery K, Lowe DB, Saha D. · · 2021 · cited 42× · PMID 33670551 · DOI 10.3390/cancers13040856
  6. Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions.
    Juric V, Murphy B. · · 2020 · cited 39× · PMID 35582046 · DOI 10.20517/cdr.2019.105
  7. Targeting CDK4/6 for Anticancer Therapy.
    Qi J, Ouyang Z. · · 2022 · cited 32× · PMID 35327487 · DOI 10.3390/biomedicines10030685
  8. Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects.
    Pineda E, Domenech M, Hernández A, Comas S, et al · · 2023 · cited 27× · PMID 36721854 · DOI 10.2147/ott.s366371

Verify or expand the search:

Other trials of Abemaciclib

Trials testing the same drug.

Other recruiting trials for GBM

Currently open trials in the same condition.

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04074785.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing